🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)

ARC-10

Phase 3 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab) for Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer is a Phase 3 program (small_molecule) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcus Biosciences
Indication
Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials